PD-L1 Testing in Cancer

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations

Medicine, Immunology, Oncology +17

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text

Medicine, Immunology, Oncology +17

Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.

Tanguy Y. Seiwert, Robert I. Haddad, Shilpa Gupta et al. · Journal of Clinical Oncology · 2015 · 103 citations

Medicine, Oncology, Pharmacotherapy +12

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort.

Neil H. Segal, Sai‐Hong Ignatius Ou, Ani Sarkis Balmanoukian et al. · Journal of Clinical Oncology · 2015 · 79 citations

Medicine, Oncology, Pharmacology +17

US FDA Perspective on Challenges in Co-Developing <i>In Vitro</i> Companion Diagnostics and Targeted Cancer Therapeutics

Reena Philip, Lea Carrington, Maria Chan · Bioanalysis · 2011 · 40 citations

Medicine, Molecular Medicine, Oncology +17